Answers are grounded in this paper and cite their sources.
Research discusses dna methylation and its potential as a diagnostic biomarker for mesothelioma, highlighting challenges.
Malignant mesothelioma is a rare tumor that is highly correlated with asbestos exposure. Due to the insidious early symptoms, mesothelioma is usually diagnosed in the advanced stages of the disease. Therefore, there is an urgent need for some early detection biomarkers to assist in the diagnosis of mesothelioma. The detection of DNA methylation can be one of the new research directions. This article provides a comprehensive discussion on the research progress of DNA methylation in malignant mesothelioma, including genes that can serve as diagnostic markers for malignant mesothelioma and the current problems in clinical application. It also provides new insights for future research directions using DNA methylation as a diagnostic marker for mesothelioma.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: